Krasner Alan Seth 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Jan 21, 2022
Insider Transaction Report
Form 4
Krasner Alan Seth
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2022-01-19$12.01/sh+6,700$80,467→ 15,011 total - Sale
Common Stock
2022-01-19$21.21/sh−6,700$142,080→ 8,311 total - Exercise/Conversion
Non-qualified stock option (Right to Buy)
2022-01-19−6,700→ 160,473 totalExercise: $12.01Exp: 2028-06-15→ Common stock (6,700 underlying)
Footnotes (4)
- [F1]The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
- [F2]Includes 1,928 shares acquired under the Issuer's Employee Stock Purchase Plan since the last Section 16 filing by the Reporting Person.
- [F3]Represents the weighted average sale price for the entire number of shares sold. The actual sales prices range between $20.77 and $21.68. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
- [F4]Stock option granted June 16, 2018 with 25% vesting on the first anniversary of the grant date and the remainder vesting in a series of thirty-six (36) successive equal monthly installments thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.